Kidney Today Blog

AKF is proud to launch the next step of the UCKD Project: the UCKD Coalition, which is comprised of 15 organizations and individuals who will work together to s...

AKF Clinical Scientist in Nephrology Fellow Christine P. Limonte describes some of the advances in understanding and treating diabetic kidney disease in the las...

AKF Ambassador Patrick Gee discusses his experience participating in a clinical trial and why it is important for more people of color to participate in them.

AKF is expanding its health equity efforts to further increase awareness of the importance of participating in clinical trials, particularly for communities of ...

Good news for people on dialysis who experience debilitating itching. The FDA approved Cara Therapeutics' injection IV KORSUVA (difelikefalin) for people r...

This month, the American Kidney Fund (AKF) is putting a spotlight on Fabry disease. While doctors once thought that only men could get Fabry disease, we now kno...

The FDA's treatment approval of Oxlumo™ (lumasiran) by Alnylam Pharmaceuticals is the first therapy for people with the rare genetic disease primary hypero...

Supplements and alternative drugs can interact with prescribed drugs or cause harm in other ways.

For the first time, there is a treatment for autosomal dominant polycystic kidney disease (ADPKD).